To investigate whether aberrant PGR activity is a mechanism of castrate resistant prostate cancer development, a phase I/II clinical trial has just been initiated to test the effect of the anti-progestin, onapristone, in patients with this condition (http://clinicaltrials.gov/show/NCT02049190). Here, PGR is linked to prostate carcinoma.